Answers are grounded in this paper and cite their sources.
Background: Long-acting insulin analogues have been widely used in patients with type 2 diabetes with reduced insulin secretion. In these patients, hypoglycemia may occur during the night when they do not consume food. We have already reported that anti-insulin antibodies developed at a fairly high frequency in patients with type 2 diabetes treated with insulin analogues. Therefore, clinical factors associated with nocturnal hypoglycemia, including anti-insulin antibodies, were searched in patients with type 2 diabetes treated with insulin analogues. Methods: The subjects consisted of 55 patients with type 2 diabetes with relatively stable glucose control treated with long-acting insulin analogues and 15 non-diabetic subjects. Using a continuous glucose monitoring, glucose fluctuation was observed for 10 days. Hypoglycemia was defined as a glucose monitoring level of less than 54 mg/dL for more than 15 min. Results: Nocturnal (duration 6 h, from midnight to 6 a.m.) hypoglycemia was observed in 13 patients (23.6%). All of the cases were unrecognized. Daytime (duration 18 h, from 6 a.m. to midnight) hypoglycemia was also observed in 14 patients (25.5%). Stratified analysis and logistic regression analysis disclosed that anti-insulin antibodies were significantly associated with nocturnal hypoglycemia in contrast to daytime hypoglycemia, which was not associated with anti-insulin antibodies but associated with lower HbA1c. That is, the frequency of nocturnal hypoglycemia was significantly higher in the negative group and lower in the positive group of the anti-insulin antibodies. Conclusions: These results suggest that circulating anti-insulin antibodies protect against nocturnal hypoglycemia.
No takes yet. Share an insight, caveat, or question.
Sanke et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: